Tower Research Capital LLC TRC Sells 41,663 Shares of Haleon plc (NYSE:HLN)

Tower Research Capital LLC TRC lowered its holdings in shares of Haleon plc (NYSE:HLN - Free Report) by 84.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,793 shares of the company's stock after selling 41,663 shares during the period. Tower Research Capital LLC TRC's holdings in Haleon were worth $74,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in HLN. Sierra Ocean LLC acquired a new position in shares of Haleon in the 4th quarter worth approximately $26,000. Geneos Wealth Management Inc. purchased a new stake in Haleon in the 4th quarter valued at $35,000. Spire Wealth Management bought a new stake in Haleon in the 4th quarter worth about $39,000. FIL Ltd increased its position in shares of Haleon by 45.7% during the fourth quarter. FIL Ltd now owns 4,049 shares of the company's stock valued at $39,000 after acquiring an additional 1,270 shares during the last quarter. Finally, Addison Advisors LLC boosted its holdings in shares of Haleon by 28.7% in the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock worth $47,000 after buying an additional 1,106 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on HLN shares. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Morgan Stanley raised Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 target price for the company in a research note on Friday. Hsbc Global Res lowered shares of Haleon from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. HSBC reissued a "hold" rating on shares of Haleon in a research note on Wednesday, March 5th. Finally, Barclays reiterated an "overweight" rating on shares of Haleon in a report on Tuesday. Five equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Haleon has a consensus rating of "Moderate Buy" and a consensus price target of $11.25.

Haleon Price Performance

Haleon stock opened at $10.75 on Friday. Haleon plc has a 1 year low of $8.24 and a 1 year high of $10.85. The stock has a market cap of $48.48 billion, a price-to-earnings ratio of 31.62, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24. The firm has a 50-day moving average of $10.20 and a two-hundred day moving average of $9.84. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58.

Haleon (NYSE:HLN - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The firm had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.38 billion. On average, research analysts forecast that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The firm also recently declared a -- dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be given a dividend of $0.1166 per share. The ex-dividend date of this dividend is Friday, April 25th. This is a positive change from Haleon's previous -- dividend of $0.05. This represents a yield of 1.6%. Haleon's payout ratio is presently 58.97%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

Want to see what other hedge funds are holding HLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haleon plc (NYSE:HLN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.